JP2010538062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538062A5 JP2010538062A5 JP2010523991A JP2010523991A JP2010538062A5 JP 2010538062 A5 JP2010538062 A5 JP 2010538062A5 JP 2010523991 A JP2010523991 A JP 2010523991A JP 2010523991 A JP2010523991 A JP 2010523991A JP 2010538062 A5 JP2010538062 A5 JP 2010538062A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- azithromycin
- release solid
- sustained
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 238000009472 formulation Methods 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 43
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 42
- 229960004099 azithromycin Drugs 0.000 claims description 42
- 230000009246 food effect Effects 0.000 claims description 12
- 235000021471 food effect Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims 57
- 239000012730 sustained-release form Substances 0.000 claims 54
- 238000013268 sustained release Methods 0.000 claims 53
- 238000002360 preparation method Methods 0.000 claims 40
- 238000000034 method Methods 0.000 claims 27
- 235000020925 non fasting Nutrition 0.000 claims 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims 7
- 206010000496 acne Diseases 0.000 claims 7
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 229910000831 Steel Inorganic materials 0.000 claims 1
- 229940085314 azithromycin 250 mg Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000012439 solid excipient Substances 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96750407P | 2007-09-05 | 2007-09-05 | |
| US12/002,417 US8124123B2 (en) | 2007-09-05 | 2007-12-17 | Controlled release azithromycin solid dosages forms |
| PCT/US2008/009169 WO2009032037A1 (en) | 2007-09-05 | 2008-07-30 | Controlled release azithromycin solid dosages forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538062A JP2010538062A (ja) | 2010-12-09 |
| JP2010538062A5 true JP2010538062A5 (enExample) | 2011-09-15 |
Family
ID=40407900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523991A Revoked JP2010538062A (ja) | 2007-09-05 | 2008-07-30 | 徐放性アジスロマイシン固形製剤 |
| JP2010524023A Withdrawn JP2010538066A (ja) | 2007-09-05 | 2008-09-04 | 皮膚疾患治療用アジスロマイシン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524023A Withdrawn JP2010538066A (ja) | 2007-09-05 | 2008-09-04 | 皮膚疾患治療用アジスロマイシン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8124123B2 (enExample) |
| EP (2) | EP2197420A4 (enExample) |
| JP (2) | JP2010538062A (enExample) |
| KR (2) | KR20100063088A (enExample) |
| CN (2) | CN101861138A (enExample) |
| AR (1) | AR068368A1 (enExample) |
| AU (2) | AU2008295579A1 (enExample) |
| BR (1) | BRPI0816268A2 (enExample) |
| CA (2) | CA2697496A1 (enExample) |
| RU (2) | RU2010109358A (enExample) |
| WO (2) | WO2009032037A1 (enExample) |
| ZA (2) | ZA201001649B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1575569T1 (sl) | 2002-12-13 | 2010-12-31 | Durect Corp | Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale |
| EP2067471B1 (en) | 2007-12-06 | 2018-02-14 | Durect Corporation | Oral pharmaceutical dosage forms |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| JP7258561B2 (ja) | 2016-07-06 | 2023-04-17 | オリエント ファーマ シーオー．，エルティーディー． | 薬物組成物、バリヤー層及び薬物層を有している経口投与形態 |
| IL314380A (en) * | 2016-10-06 | 2024-09-01 | Orbus Therapeutics Inc | Preparations for administration of aflornithine |
| CN109875970B (zh) * | 2019-01-08 | 2021-08-06 | 石家庄四药有限公司 | 阿奇霉素固体制剂及其制备方法 |
| CN113116859B (zh) * | 2021-04-12 | 2022-08-30 | 海南普利制药股份有限公司 | 阿奇霉素丸芯包衣制剂 |
| WO2023283427A2 (en) * | 2021-07-09 | 2023-01-12 | Verdure Biotech, Inc. | Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| EP0758244B2 (en) * | 1994-05-06 | 2008-02-13 | Pfizer Inc. | Controlled-release dosage forms of azithromycin |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| AU7888298A (en) * | 1997-01-03 | 1998-07-31 | Elan Corporation, Plc | Sustained release cisapride minitablet formulation |
| US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| BRPI0414000B8 (pt) * | 2003-08-29 | 2021-05-25 | Lifecycle Pharma As | composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica |
| US20050239723A1 (en) * | 2004-04-27 | 2005-10-27 | Amin Avinash N | Compositions and methods useful for treatment of acne |
| EP1830815A1 (en) | 2004-12-21 | 2007-09-12 | Pfizer Products Incorporated | Enteric coated azithromycin multiparticulates |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| JP5114382B2 (ja) * | 2005-04-08 | 2013-01-09 | アボット・ラボラトリーズ | フェノフィブリン酸および／またはそれの塩を含む経口医薬製剤 |
| US20070105788A1 (en) * | 2005-11-09 | 2007-05-10 | Serena Mraz-Gernhard | Azithromycin for treatment of granulomatous rosacea |
| US7704959B2 (en) * | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
-
2007
- 2007-12-17 US US12/002,417 patent/US8124123B2/en not_active Expired - Fee Related
-
2008
- 2008-07-30 CN CN200880105792A patent/CN101861138A/zh active Pending
- 2008-07-30 JP JP2010523991A patent/JP2010538062A/ja not_active Revoked
- 2008-07-30 RU RU2010109358/15A patent/RU2010109358A/ru unknown
- 2008-07-30 WO PCT/US2008/009169 patent/WO2009032037A1/en not_active Ceased
- 2008-07-30 BR BRPI0816268A patent/BRPI0816268A2/pt not_active IP Right Cessation
- 2008-07-30 AU AU2008295579A patent/AU2008295579A1/en not_active Abandoned
- 2008-07-30 CA CA2697496A patent/CA2697496A1/en not_active Abandoned
- 2008-07-30 KR KR1020107006490A patent/KR20100063088A/ko not_active Withdrawn
- 2008-07-30 EP EP08780336A patent/EP2197420A4/en not_active Withdrawn
- 2008-09-04 EP EP08829925A patent/EP2197453A4/en not_active Withdrawn
- 2008-09-04 CN CN200880105803A patent/CN101835475A/zh active Pending
- 2008-09-04 JP JP2010524023A patent/JP2010538066A/ja not_active Withdrawn
- 2008-09-04 WO PCT/US2008/010355 patent/WO2009032268A1/en not_active Ceased
- 2008-09-04 AU AU2008296903A patent/AU2008296903A1/en not_active Abandoned
- 2008-09-04 KR KR1020107006491A patent/KR20100054842A/ko not_active Withdrawn
- 2008-09-04 RU RU2010109359/15A patent/RU2010109359A/ru not_active Application Discontinuation
- 2008-09-04 AR ARP080103847A patent/AR068368A1/es not_active Application Discontinuation
- 2008-09-04 CA CA2697537A patent/CA2697537A1/en not_active Abandoned
-
2010
- 2010-03-08 ZA ZA2010/01649A patent/ZA201001649B/en unknown
- 2010-03-10 ZA ZA2010/01705A patent/ZA201001705B/en unknown
-
2012
- 2012-01-25 US US13/357,722 patent/US20120121702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010538062A5 (enExample) | ||
| ES2742525T3 (es) | Composiciones de corticosteroides administradas oralmente | |
| JP6105761B2 (ja) | 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法 | |
| TWI686215B (zh) | 祛鐵斯若(deferasirox)之口服配方 | |
| CN101977593B (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
| CN109310642B (zh) | 美沙拉嗪的口服药物组合物 | |
| JP2011513391A (ja) | ミコフェノラートを含有する徐放性医薬組成物およびその方法 | |
| CN102869349A (zh) | 耐酒精的肠溶药物组合物 | |
| KR20130006638A (ko) | 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 | |
| US10071058B2 (en) | Controlled-release solid dosage forms of mesalamine | |
| JP2007091758A5 (enExample) | ||
| JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
| JP2005528430A5 (enExample) | ||
| CN101686944A (zh) | 熊去氧胆酸的高剂量组合物 | |
| JP2008519070A5 (enExample) | ||
| JP2015500853A (ja) | 即時放出マルチユニットペレットシステム | |
| CN106794149A (zh) | 含ω‑3脂肪酸酯和他汀类的口服给药复合制剂 | |
| CN107205937A (zh) | 包含富马酸二甲酯的药物珠粒制剂 | |
| CN101861138A (zh) | 控释的阿奇霉素固体剂型 | |
| JP7021108B2 (ja) | ニコチンアミドの経口薬学的組成物 | |
| CN101932322A (zh) | 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物 | |
| WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
| TW201542212A (zh) | 包括恩曲他濱、泰諾福韋、地瑞那韋與利托那韋的單位劑量形式以及包括地瑞那韋與利托那韋的單體錠劑 | |
| JP2008519069A5 (enExample) | ||
| JP2003510347A (ja) | 抗炎症医薬品製剤 |